We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Register to vote Register by 18 June to vote in the General Election on 4 July.
Population screening programmes can cause harms as well as benefits, which need to be weighed up by the UK National Screening Committee (UK NSC).
Resources to help local commissioners achieve value for money by estimating the return on investment (ROI) and cost-effectiveness of public health programmes.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (21 May 2024) launched a four-week consultation which will support improved safety for certain high risk in vitro diagnostic (IVD) devices.
The VDEC clinical evaluation team works to support vaccine and therapeutic development by providing expertise in immunological and functional assays used to support clinical trials (Phase I to IV)
Guidance on who to test for Zika virus infection and which samples to collect.
Incapacity Benefit is help if you could not work because of an illness or disability before 31 January 2011 - it's being replaced with Employment and Support Allowance (ESA).
The RPC and Better Regulation Executive (BRE) have compiled a collection of links that may be useful for departments to use when writing impact assessments.
Benznidazole Evaluation for Interrupting Trypanosomiasis evaluates the safety of benznidazole in patients with Chagasic cardiomyopathy
This guide sets out what population screening is, how it works, and its limitations.
How to use a quasi-experimental study to evaluate your digital health product.
These published standards relate to a number of KPIs in the VMD Deliverables and KPI document.
Information on good laboratory, manufacturing and distribution practice, good pharmacovigilance practice (GPvP), out-of-specification investigations, inspection metrics and fees.
Information about the range of help and support available from the FE Commissioner, Department for Education and delivery partners.
What you need to know before you can place a medical device on the Great Britain market with a UKCA mark.
Information to assist with the laboratory diagnosis of Lyme disease and requirements for sample submission.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).